Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study

8 May 2024

Abstract excerpt

BACKGROUND: There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR) stabilizers or gene silencers. While many patients may be on both classes of medications, there is no data available on the safety and efficacy of combination therapy. OBJECTIVES: To describe ATTRv patient and TTR-targeted therapy characteristics in a US cohort, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Dermatological and Skeletal Disorders
Share to Parathyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38720335
DOI: 10.1186/s13023-024-03198-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studyPMID 38720335Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study.Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy–2025 Update: Current Diagnostic Approaches and Emerging Therapeutic OptionsSemantic proximity Read ↗

Neuropathy Assessment and Treatment Patterns in Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

[Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv)].Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.Semantic proximity Read ↗

Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.Semantic proximity Read ↗

Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid CardiomyopathySemantic proximity Read ↗

Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.